2-ethyl-3,4-dimethyl-pyridine | 5258-15-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-ethyl-3,4-dimethyl-pyridine
• 英文别名: 2-Ethyl-3,4-dimethylpyridine
• CAS: 5258-15-1
• 化学式: C₉H₁₃N
• 分子量: 135.209
• InChiKey: RDOWRVTXAPIIKV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Inhibitors of cell proliferation, angiogenesis, fertility, and muscle contraction
  申请人：——

  公开号：US20030064989A1

  公开（公告）日：2003-04-03

  The invention concerns inhibitors of cell proliferation, angiogenesis, fertility, and muscle contraction, characterized by formula I 1 wherein, X, Y and Z independently represent C or N; ------ is an optional double bond; n is 0 or 1; R 1 , R 2 , and R 4 independently represent hydrogen, a chemical bond, C 1-10 alkyl; C 2-10 alkenyl; C 2-10 alkinyl; aryl; aryl-C 1-10 alkyl; C 3-10 heterocyclyl; C 5-10 heteroaryl; halo, CF 3 ; NO 2 ; NHC(O)R*, OR, said alkyl, alkenyl, alkinyl, aryl, arylalkyl, heterocyclyl, or heteroaryl being optionally substituted; R 3 , R 5 , and R 6 independently represent hydrogen, C 1-10 alkyl; C 2-10 alkenyl; C 2-10 alkinyl; aryl; aryl-C 1-10 alkyl; C 3-10 heterocyclyl; C 5-10 heteroaryl; halo, CF 3 ; NO 2 ; NHC(O)R*, OR, said alkyl, alkenyl, alkinyl, aryl, heterocyclyl, or heteroaryl being optionally substituted; or R 5 and R 6 together form a 5- or 6-member aryl, heterocyclyl or heteroaryl group; R is hydrogen or C 1-6 alkyl; R* is hydrogen, or C 1-6 alkyl, or OH, wherein the optional substituents are preferably selected from the group of one to three OH, C 1-6 alkyl, halo, NO 2 , C 1-6 alkoxy, and CF3, or a pharmaceutically acceptable salt thereof.

  该发明涉及细胞增殖、血管生成、生育和肌肉收缩的抑制剂，其特征在于以下公式I1： 其中，X、Y和Z独立表示C或N；------是一个可选的双键；n为0或1；R1、R2和R4独立表示氢、化学键、C1-10烷基；C2-10烯基；C2-10炔基；芳基；芳基-C1-10烷基；C3-10杂环烷基；C5-10杂芳基；卤素、三氟甲基；NO2；NHC(O)R*、OR，所述的烷基、烯基、炔基、芳基、芳基烷基、杂环烷基或杂芳基可以是可选的取代基；R3、R5和R6独立表示氢、C1-10烷基；C2-10烯基；C2-10炔基；芳基；芳基-C1-10烷基；C3-10杂环烷基；C5-10杂芳基；卤素、三氟甲基； ；NHC(O)R*、OR，所述的烷基、烯基、炔基、芳基、芳基烷基、杂环烷基或杂芳基可以是可选的取代基；或者R5和R6一起形成一个5-或6-成员的芳基、杂环烷基或杂芳基；R为氢或C1-6烷基；R*为氢、或C1-6烷基、或OH，其中可选的取代基优选从一个到三个OH、C1-6烷基、卤素、 、C1-6烷氧基和三氟甲基中选择，或其药学上可接受的盐。
• HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF
  申请人：iOmx Therapeutics AG

  公开号：EP3643713A1

  公开（公告）日：2020-04-29

  The invention relates to kinase inhibitors, in particular inhibitors of protein kinases including the protein-tyrosine kinases LCK, ABL, SRC, KIT, SIK-family and/or their mutants. Although structurally similar to dasatinib, the kinase inhibitors of the invention can display one or more certain properties distinct to dasatinib. Also, the invention relates to pharmaceutical compositions that comprise one or more of the kinase inhibitors. The kinase inhibitors or pharmaceutical compositions of the invention may be used in the treatment of a disorder or condition, such as a proliferative disorder, for example, a leukaemia or solid tumour. The kinase inhibitors or pharmaceutical compositions may be used in a treatment regimen that corresponds to, is similar to or is distinct from that used with dasatinib for a corresponding disorder, and in particular may be used in a combination treatment regimen together with one or more additional therapeutic agents, such as immune-checkpoint inhibitors.

  本发明涉及激酶抑制剂，特别是蛋白激酶的抑制剂，包括LCK、ABL、SRC、KIT、SIK家族和/或它们的突变体。虽然在结构上类似于达沙替尼，但本发明的激酶抑制剂可以表现出与达沙替尼不同的一种或多种特定性质。此外，本发明涉及包含一种或多种激酶抑制剂的制药组合物。本发明的激酶抑制剂或制药组合物可用于治疗疾病或病况，例如增生性疾病，例如白血病或实体肿瘤。本发明的激酶抑制剂或制药组合物可用于与达沙替尼用于相应疾病的治疗方案相对应、类似或不同的治疗方案中，并且特别可用于与一种或多种额外的治疗药物，例如免疫检查点抑制剂一起使用的联合治疗方案中。
• Insecticidal Triazines and Pyrimidines
  申请人：Kennedy Robert M.

  公开号：US20120022066A1

  公开（公告）日：2012-01-26

  The present invention describes novel triazines, their related pyrimidines and their use in controlling insects. This invention also includes new synthetic procedures, intermediates for preparing the compounds, pesticide compositions containing the compounds, and methods of controlling insects using the compounds.

  本发明描述了新型三嗪、相关的嘧啶及其在控制昆虫方面的应用。该发明还包括新的合成方法、制备化合物的中间体、含有该化合物的杀虫剂组合物以及使用该化合物控制昆虫的方法。
• KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
  申请人：Amgen Inc.

  公开号：US20210009577A1

  公开（公告）日：2021-01-14

  Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

  本文提供KRAS G12C抑制剂，其组成，以及使用方法。这些抑制剂对于治疗多种疾病有用，包括胰腺癌，结直肠癌和肺癌。
• Method for manufacturing pyridine and pyridine derivatives from alkynes and cyano compounds in the presence of complex cobalt or rhodium compounds with ligands containing boron
  申请人：Studiengesellschaft Kohle mbH

  公开号：EP0064268A1

  公开（公告）日：1982-11-10

  The preparation of pyridine and pyridine derivatives from alkynes and cyano compounds including HCN is disclosed. The process can be carried out in the presence of a cobalt or rhodium catalyst having at least one ligand with one or more boron atoms. Certain new cobalt or rhodium catalysts containing such ligand are also disclosed. Also disclosed is a process for the formation of 2-aminopyridine by contacting acetylene with cyanamide such as in the presence of a cobalt or rhodium catalyst which has at least one ligand with one or more boron atoms.

  本发明公开了由炔烃和氰基化合物（包括 HCN）制备吡啶和吡啶衍生物的方法。该工艺可在钴或铑催化剂存在下进行，钴或铑催化剂至少有一个配位体含有一个或多个硼原子。还公开了某些含有此类配位体的新型钴或铑催化剂。还公开了一种通过乙炔与氰酰胺接触生成 2-氨基吡啶的工艺，例如在钴或铑催化剂存在下，该催化剂具有至少一种含有一个或多个硼原子的配位体。